United Therapeutics insiders just torched $186M in stock over 30 days — that's not "portfolio rebalancing," that's a five-alarm fire drill. Meanwhile, CoreWeave's CSO quietly liquidated 900,000 shares while Wall Street swoons over AI infrastructure fairy tales. Here's the brutal truth: when C-suite executives sprint for the exits this hard, the accounting chickens come home to roost within quarters.

Research these companies